ABCR  Vol.7 No.2 , April 2018
Profile of Patients with Breast Cancer Brain Metastasis in Abidjan
Abstract: Patients with breast cancer will develop brain metastases in 15% - 25% of cases. Objective: To identify the profile of patients with breast cancer brain metastasis. Method: Retrospective study over 4 years in the oncology department of Treichville Hospital. All patients with breast carcinoma who had a brain metastasis during their cancer management were included. Results: 41 cases of breast carcinoma brain metastasis were collected. Patients were older than 40 years in 78% of cases. Family history of breast cancer was found in 7% of patients. More than 80% of patients had consulted with T3 and T4 tumor masses, with 100% of cases of node involvement. The brain was the second site of metastasis. The tumors were Triple negative in 48%, Her2 positive in 36% and luminal in 16%. Brain metastases were of late onset in the majority of cases (68%). They were clinically characterized by headaches (100%), most often included in an intracranial hypertension syndrome (52%). They were multiple (60%). Therapeutically, no surgery was performed on the metastases. Three patients received whole brain radiation therapy. All patients received systemic therapy. In terms of response, 30 cases of progression were observed after treatment and 2 cases of complete response were obtained. Survival from onset of brain metastasis was of 75% at 3 months and 2% at 12 months. Patients with longer survival rates were over 40 years old with triple negative breast cancer. Conclusion: Brain metastasis from breast cancer most often occurs in a particular clinical and pathological context in our countries.
Cite this paper: Kouassi, K. , Touré, M. , Seka, E. , Kimso, O. , Oseni, M. , Odo, B. , Kagambega, A. and Adoubi, I. (2018) Profile of Patients with Breast Cancer Brain Metastasis in Abidjan. Advances in Breast Cancer Research, 7, 201-210. doi: 10.4236/abcr.2018.72012.

[1]   Lin, N.U., Bellon, J.R. and Winer, E.P. (2004) CNS Metastases in Breast Cancer. Journal of Clinical Oncology, 22, 3608-3617.

[2]   Barnholtz-Sloan, J.S., Sloan, A.E., Davis, F.G., Vigneau, F.D., Lai, P. and Sawaya, R.E. (2004) Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. Journal of Clinical Oncology, 22, 2865-2872.

[3]   Petit, T. (2010) Métastases cérébrales et cancer du sein. La Lettre du Cancérologue, XIX, 134-137.

[4]   Pestalozzi, B.C., Zahrieh, D., Price, K.N., Holmberg, S.B., Lindtner, J. and Collins, J. (2006) Identifying Breast Cancer Patients at Risk for Central Nervous System (CNS) Metastases in Trials of the International Breast Cancer Study Group (IBCSG). Annals of Oncology, 17, 935-944.

[5]   Evans, A.J., James, J.J., Cornford, E.J., Chan, S.Y., Burrell, H.C. and Pinder, S.E. (2004) Brain Metastases from Breast Cancer: Identification of a High-Risk Group. Clinical Oncology (Royal College of Radiologists (Great Britain)), 16, 345-349.

[6]   Albiges, L., André, F., Balleyguier, C., Gomez-Abuin, G., Chompret, A. and Delaloge, S. (2005) Spectrum of Breast Cancer Metastasis in BRCA1 Mutation Carriers: Highly Increased Incidence of Brain Metastases. Annals of Oncology off Journal European Society of Medical Oncology ESMO, 16, 1846-1847.

[7]   Hsairi, M., Fakhfakh, R., Ben Abdalah, M., Jlidi, R. and Sellami, A. (2002) Assessment of Cancer Incidence in Tunisia 1993-1997. La Tunisie médicale, 80, 57-64.

[8]   Touré, M., Kouassi, Y.K.K., Séka, E.N., Bambara, T.A., Yao, I., Djanhan, L.E. and Adoubi, I. (2015) Caractéristiques épidémio-cliniques des cancers du sein triple négatif à Abidjan. Carcinologie Clinique en Afrique, 14, 32-36.

[9]   Gabos, Z., Sinha, R. and Hanson, J. (2006) Prognostic Significance of Human Epidermal Growth Factor Receptor Positivity for the Development of Brain Metastasis after Newly Diagnosed Breast Cancer. Journal of Clinical Oncology, 24, 5658-5663.

[10]   Lin, N.U., Wefel, J.S. and Lee, E.Q. (2013) Challenges Relating to Solid Tumour Brain Metastases in Clinical Trials, Part 2: Neurocognitive, Neurological, and Quality-of-Life Outcomes. A Report from the RANO Group. The Lancet Oncology, 14, e407-e416.

[11]   Schellinger, P.D., Meinck, H.M. and Thron, A. (1999) Diagnostic Accuracy of MRI Compared to CCT in Patients with Brain Metastases. Journal of Neurooncology, 44, 275-281.

[12]   Davis, P.C., Hudgins, P.A. and Peterman, S.B. (1991) Diagnosis of Cerebral Metastases: Double Dose Delayed CT vs. Contrast-Enhanced MR Imaging. American Journal of Neuroradiology, 12, 293-300.

[13]   Ranjan, T. and Abrey, L. (2009) Current Management of Metastatic Brain Disease. Neurotherapeutics, 6, 598-603.

[14]   Belkacémi, Y. and Kuten, A. (2008) Are Volumetric Changes of Brain Metastases the Best Evaluation of Efficacy? Journal of Clinical Oncology, 26, 5137-5138.

[15]   Pestalozzi, B. and Castiglione, M. (2008) On Behalf of the ESMO Guidelines Working Group. Primary Breast Cancer: ESMO Clinical Recommendations for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 19, ii7-ii10.